Represents f irst s tep towards a potential c linical t reatment of l ocally a dvanced p ancreatic c ancer LYON, France, January 13, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announces the publication of positive pre-clinical
Company announces s everal k ey U.S. Focal One installations during Q4 LYON, France, January 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent Focal One placements and the initiation of treatments at select
LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference,
Year-to-date revenue of approximately EUR 30.1 million (USD 35.9 million) increased 14.4% year-over-year Q3 revenue of EUR 9.4 million (USD 11.1 million), flat with Q3 2020, reflecting lingering impact of COVID-19 on capital equipment sales Year-to-date US HIFU treatment volumes increased 58% over
Company to host conference call and webcast on Thursday, November 18, at 8:30 am ET LYON, France, November 10, 20 21 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2021
Brings advanced focal ablation to prostate cancer patients in the Pacific Northwest LYON, France, September 28, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that University of Washington Medicine has acquired the company’s
Data demonstrate superiority of HIFU versus radical prostatectomy among prostate cancer patients LYON, France, September 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company’s Focal One and ExactVu technologies
LYON, France, September 7, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that management will present at the following investor conferences during the month of September 2021: H.C.
Total revenue for the first half 2021 of EUR 20.7 million (USD $24.8 million) increased 22.5% over the same period of the prior year Net income was EUR 0.4 million (USD 0.4 million), or EUR 0.01 per diluted share, for the first half of 2021 Cash balance of EUR 45 million (USD $53.3 million) as of
Total company second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million) increased 11.8% year-over-year; first half 2021 total company revenue of EUR 20.7 million (USD $24.8 million) increased 22.5% During the second quarter, U.S.
